Matrixyl 3000
Overview
Matrixyl 3000 is not a single molecule but a two-peptide system: Palmitoyl Tripeptide-1 (Pal-GHK) paired with Palmitoyl Tetrapeptide-7 (Pal-GQPR). The idea studied in the literature is complementary action — one peptide is a collagen-oriented matrikine, the other is investigated for calming the inflammatory signalling that degrades matrix — so together they are researched as a broader approach to dermal-matrix support than either alone.
Chemical Profile
The blend contains two independently synthesized palmitoylated peptides, typically combined at about a 6 : 4 ratio (Tripeptide-1 : Tetrapeptide-7).
| Component 1 — Palmitoyl Tripeptide-1 | Value |
|---|---|
| CAS number | 147732-56-7 |
| INCI name | Palmitoyl Tripeptide-1 |
| Amino-acid sequence | Pal-Gly-His-Lys-OH (Pal-GHK) |
| Molecular formula | C₃₀H₅₃N₇O₆ |
| Molecular weight | 673.83 g/mol |
| Component 2 — Palmitoyl Tetrapeptide-7 | Value |
|---|---|
| CAS number | 221227-05-0 |
| INCI name | Palmitoyl Tetrapeptide-7 |
| Amino-acid sequence | Pal-Gly-Gln-Pro-Arg-OH (Pal-GQPR) |
| Molecular formula | C₃₀H₅₂N₈O₇ |
| Molecular weight | 520.68 g/mol |
- Class
- Dual palmitoylated matrikine system
- Component 1
- Pal-Tripeptide-1 — collagen-oriented
- Component 2
- Pal-Tetrapeptide-7 — anti-inflammatory research
- Typical blend ratio
- ≈ 6 : 4 (T1 : T7)
- Typical route
- Topical
- Reference trade name
- Matrixyl™ 3000 (Sederma / Ashland)
Mechanism of Action
The two peptides are studied for different but reinforcing roles. Palmitoyl Tripeptide-1 carries the GHK sequence and is investigated as a matrikine that signals collagen synthesis; Palmitoyl Tetrapeptide-7 is modelled on an immunoglobulin fragment and is studied for damping pro-inflammatory cytokines that would otherwise drive matrix breakdown.
| Palmitoyl Tripeptide-1 (collagen) | Research description |
|---|---|
| Primary target | Fibroblast TGF-β signalling |
| Mechanism | Matrikine cue for procollagen synthesis |
| Collagen types | Associated with collagen I, III and IV |
| Wider ECM | Fibronectin, elastin and laminin in models |
| Palmitoyl Tetrapeptide-7 (anti-inflammatory) | Research description |
|---|---|
| Primary target | Pro-inflammatory cytokine signalling (e.g. IL-6, IL-1β) |
| Mechanism | Studied for downregulating cytokine output from stimulated fibroblasts |
| Origin mimic | Modelled on an immunoglobulin-G heavy-chain fragment |
| Protective role | Explored for limiting cytokine-driven collagen degradation |
The research rationale for the blend is synergy: one peptide is investigated for building matrix while the other is investigated for protecting it, so the combination is studied as more complete than a single matrikine.
Pharmacology
| Parameter | Palmitoyl Tripeptide-1 | Palmitoyl Tetrapeptide-7 |
|---|---|---|
| logP | ≈ 4.0 (lipophilic) | ≈ 3.8 (lipophilic) |
| Topical bioavailability | ~5–10% | ~5–10% |
| Stability | High (palmitoyl protection) | High (palmitoyl protection) |
| Metabolism | Proteolytic breakdown | Proteolytic breakdown |
| Route | Topical | Topical |
Research Evidence
Matrixyl 3000 is studied both as a two-peptide system and by its individual components, in cell-based (preclinical) and human (clinical) research.
Combined ECM research
Studied where both collagen synthesis and matrix protection are the endpoints, rather than collagen alone.
Anti-inflammatory tone
The Tetrapeptide-7 component is used to explore cytokine modulation in fibroblast models.
Formulation development
Used in clinical-style anti-aging formulation research as a ready dual-peptide system.
Matrikine comparison
A frequent comparator against single matrikines such as Matrixyl.
Preclinical research — representative models and what they investigate:
| Model | Research focus | Reference |
|---|---|---|
| Human dermal fibroblasts | Collagen synthesis (Tripeptide-1 component) | Katayama K, et al. (1993) |
| Stimulated fibroblasts | Pro-inflammatory cytokine (IL-6) modulation (Tetrapeptide-7) | Schagen SK (2017, review) |
| Aged human fibroblasts | ECM-related gene-expression profile | Gorouhi F, Maibach HI (2009) |
| Human skin (ex vivo) | Penetration of both peptide components | Lupo MP, Cole AL (2007) |
Clinical research — the types of human study in which the blend is examined:
| Study type | Endpoints studied | Reference |
|---|---|---|
| Topical anti-aging cream | Wrinkle appearance, firmness and elasticity | Gorouhi F, Maibach HI (2009) |
| Formulation efficacy studies | Overall wrinkle severity and skin texture | Schagen SK (2017) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Collagen stimulation plus anti-inflammatory (IL-6) modulation | aged human fibroblasts | cosmetic-peptide literature |
| Comprehensive ECM / anti-aging endpoints | formulation studies | Gorouhi F, Maibach HI (2009) |
For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.
Formulation & Dosing Reference
| Parameter | Value |
|---|---|
| Typical topical concentration | 1–8% (w/w) of the blend |
| Common working range | 3–5% |
| Component ratio | ≈ 6 : 4 (Tripeptide-1 : Tetrapeptide-7) |
| Solubility in water | Poor (< 1 mg/mL) — co-solvent or emulsion needed |
| Solubility in DMSO | ≥ 50 mg/mL |
| Recommended formulation pH | 5.0–7.0 |
| Storage (powder) | 2–8°C, sealed, dry, protected from light |
Safety Profile
| Assessment | Reported result |
|---|---|
| Acute oral toxicity (rat) | LD50 > 2000 mg/kg |
| Dermal irritation (rabbit) | Non-irritant at 8% |
| Ocular irritation (rabbit) | Mild, transient |
| Skin sensitization (GPMT) | Non-sensitizing |
| Mutagenicity (Ames) | Negative |
| INCI status | Both components approved cosmetic ingredients |
Physicochemical Properties
| Property | Pal-Tripeptide-1 | Pal-Tetrapeptide-7 |
|---|---|---|
| Appearance | White to off-white powder | White to off-white powder |
| Molecular weight | 673.8 Da | 520.7 Da |
| logP | ≈ 4.0 | ≈ 3.8 |
| Solubility in water | < 1 mg/mL | < 1 mg/mL |
| Solubility in DMSO | ≥ 50 mg/mL | ≥ 50 mg/mL |
Synthesis & Manufacturing
The two peptides are synthesized separately by solid-phase peptide synthesis, each palmitoylated at the N-terminus, purified, and then combined at the target ratio.
| Step | Detail (both components) |
|---|---|
| Strategy | Solid-phase peptide synthesis, Fmoc/tBu chemistry |
| Resin | Wang resin (C-terminal acid) |
| Coupling | HATU / HBTU with DIPEA |
| Palmitoylation | Palmitic acid coupled to the N-terminus after final Fmoc removal |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, high-organic gradient) |
| Blending | Purified peptides combined ≈ 6 : 4 by weight (dry blend or co-lyophilization) |
Analytical Methods
Because Matrixyl 3000 is a blend, quality control characterises each peptide and confirms the ratio of the two.
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity (combined) | ≥ 95% |
| RP-HPLC | Component ratio | Two resolved peaks ≈ 6 : 4 (T1 : T7) |
| ESI-MS (positive mode) | Identity / mass | Masses consistent with both palmitoyl peptides |
| LC-MS/MS | Palmitoylation site | N-terminal palmitoylation confirmed (each component) |
| Karl Fischer | Water content | < 5% |
Representative RP-HPLC method (high-organic gradient for the palmitoylated peptides):
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 60–90% B over ~20 min · Flow rate: 1.0 mL/min
- Detection: UV 214 nm — the two components elute as separate, well-resolved peaks
Stability Data
Both components carry a protective palmitoyl group, so the blend behaves much like Matrixyl — stable as a powder and in emulsions, with pH and emulsification as the main variables.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized blend, 2–8°C, dark | ≥ 24 months | No significant degradation |
| Lyophilized blend, 25°C, dark | ≥ 12 months | Minimal degradation |
| Formulated O/W emulsion, 25°C | 12+ months | Both peptides largely retained |
| Light exposure (ICH Q1B) | Standard | Light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable |
- The palmitoyl groups protect both peptides against exopeptidases, giving good powder and emulsion stability.
- An emulsion or co-solvent is needed for aqueous systems; optimal pH is 5.0–7.0.
Selected References
Representative peer-reviewed literature relevant to the Matrixyl 3000 peptides. Listed for research reference.
- Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry, 1993.
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
- Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
- Schagen SK. Topical peptide treatments with effective anti-aging results. Cosmetics, 2017.
Quality & Supply
- Each component HPLC-characterized with a Certificate of Analysis
- Identity confirmed by LC-MS; blend ratio verifiable
- Research samples through to bulk, with worldwide delivery
- Custom ratios and packaging on request
Need Matrixyl 3000 — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
